Roskamp Institute Release: Key Clinical Trial of Alzheimer’s Disease Drug Begins in Europe

Published: Feb 14, 2012

SARASOTA, Fla.--(BUSINESS WIRE)--A research team today announced the launch of a European large-scale clinical trial of Nilvadipine, an Alzheimer’s disease drug developed at the Roskamp Institute (www.rfdn.org) in Sarasota. More than 500 Alzheimer’s patients in nine European countries will participate in the phase III trial designed to study the effectiveness of the medication.

Back to news